BRPI0818881A2 - Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo - Google Patents

Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo

Info

Publication number
BRPI0818881A2
BRPI0818881A2 BRPI0818881-5A BRPI0818881A BRPI0818881A2 BR PI0818881 A2 BRPI0818881 A2 BR PI0818881A2 BR PI0818881 A BRPI0818881 A BR PI0818881A BR PI0818881 A2 BRPI0818881 A2 BR PI0818881A2
Authority
BR
Brazil
Prior art keywords
individual
cholesterol efflux
treating
mitigating
symptoms
Prior art date
Application number
BRPI0818881-5A
Other languages
English (en)
Inventor
Jonathan D Smith
Stanley L Hazen
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of BRPI0818881A2 publication Critical patent/BRPI0818881A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0818881-5A 2007-10-23 2008-10-23 Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo BRPI0818881A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98188707P 2007-10-23 2007-10-23
PCT/US2008/080898 WO2009055538A1 (en) 2007-10-23 2008-10-23 Oxidant resistant apolipoprotein a-1 and mimetic peptides

Publications (1)

Publication Number Publication Date
BRPI0818881A2 true BRPI0818881A2 (pt) 2015-05-05

Family

ID=40336739

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818881-5A BRPI0818881A2 (pt) 2007-10-23 2008-10-23 Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo

Country Status (14)

Country Link
US (4) US8143224B2 (pt)
EP (3) EP2520587B1 (pt)
JP (1) JP5600065B2 (pt)
KR (1) KR20100100824A (pt)
CN (1) CN102177176B (pt)
AU (1) AU2008316811B2 (pt)
BR (1) BRPI0818881A2 (pt)
CA (1) CA2703962A1 (pt)
EA (1) EA201070517A1 (pt)
ES (1) ES2601830T3 (pt)
HK (1) HK1162522A1 (pt)
IL (1) IL205282A (pt)
MX (1) MX2010004514A (pt)
WO (1) WO2009055538A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004514A (es) * 2007-10-23 2010-07-28 Cleveland Clinic Foundation Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion.
US20130137628A1 (en) * 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
EP2582384B1 (en) * 2010-06-15 2016-11-23 The Cleveland Clinic Foundation Compositions and methods for treating cancer
DK2673296T3 (en) 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
WO2014011908A1 (en) * 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
WO2015032841A2 (en) * 2013-09-05 2015-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease
US20150316566A1 (en) 2014-05-02 2015-11-05 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2015175864A1 (en) 2014-05-15 2015-11-19 Cleveland Heartlab, Inc. Compositions and methods for purification and detection of hdl and apoa1
CN108350036B (zh) 2015-07-10 2022-04-08 佩蒂诺沃生物制药有限责任公司 用于改善疏水性药物功效的制剂
US10484742B2 (en) * 2016-07-26 2019-11-19 Umbo, Inc. Method and system for providing information to a user via a projection device
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding CARGOMÈRES
US20190046608A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Apomers
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US20210231691A1 (en) * 2018-06-08 2021-07-29 The Cleveland Clinic Foundation Apoa1 exchange rate assays as a diagnostic for major adverse cardiovascular events
CN115427064A (zh) 2020-04-16 2022-12-02 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗急性病况的方法
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3216226A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US20060030525A1 (en) 2004-07-23 2006-02-09 Xencor, Inc. Apolipoprotein A-I derivatives with altered immunogenicity
CN101443001B (zh) * 2006-03-20 2013-11-13 西芬克斯医药有限公司 治疗或预防炎性痛的方法
MX2010004514A (es) * 2007-10-23 2010-07-28 Cleveland Clinic Foundation Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion.

Also Published As

Publication number Publication date
US20140051624A1 (en) 2014-02-20
EP2520587B1 (en) 2016-08-10
EP2212351A1 (en) 2010-08-04
WO2009055538A1 (en) 2009-04-30
AU2008316811A1 (en) 2009-04-30
US8143224B2 (en) 2012-03-27
IL205282A (en) 2016-02-29
US20120264677A1 (en) 2012-10-18
US20090149390A1 (en) 2009-06-11
EP2573113A3 (en) 2013-07-24
CA2703962A1 (en) 2009-04-30
IL205282A0 (en) 2010-12-30
US9051393B2 (en) 2015-06-09
EA201070517A1 (ru) 2010-12-30
EP2520587A2 (en) 2012-11-07
JP5600065B2 (ja) 2014-10-01
ES2601830T3 (es) 2017-02-16
KR20100100824A (ko) 2010-09-15
US20160024182A1 (en) 2016-01-28
US8536117B2 (en) 2013-09-17
EP2212351B1 (en) 2017-09-13
EP2573113A2 (en) 2013-03-27
EP2520587A3 (en) 2013-04-03
CN102177176A (zh) 2011-09-07
US9522950B2 (en) 2016-12-20
HK1162522A1 (en) 2012-08-31
AU2008316811B2 (en) 2015-01-22
CN102177176B (zh) 2014-05-07
JP2011500832A (ja) 2011-01-06
MX2010004514A (es) 2010-07-28

Similar Documents

Publication Publication Date Title
BRPI0818881A2 (pt) Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo
WO2011059836A3 (en) T cell receptor-deficient t cell compositions
WO2010065491A3 (en) Methods of treating inflammatory disorders
BRPI1014658A2 (pt) "método para aperfeiçoar a tolerância ao estresse de intrôgenio em uma planta, método para aperfeiçoar a tolerância ao estresse de nitrogênio sob condições com pouco nitrogênio, cassete de expressão, construto, célula vegetal, planta e método de inibição da produção de etileno em uma planta."
BR112012001329A2 (pt) métodos para obter células com uma potência desejada, para tratar inflamação em um sujeito, para construir um banco de células, para descoberta de droga e para aumentar a potência de uma célula, e, composição.
WO2009073808A3 (en) Compositions and methods to modulate cell membrane resealing
WO2007143724A3 (en) Compositions and methods to enhance reverse cholesterol transport
WO2011046616A3 (en) Methods for modulating bacterial infection
BRPI0819526A2 (pt) "fragmento de ácido nucléico isolado, construção recombinante, célula de planta e método para reduzir a expressão de uma sequência alvo"
BRPI0811364A2 (pt) "separador de aço inoxidável para uma célula de combustível e método para manufaturar o separador de aço inoxidável para célula de combustível"
WO2013177594A3 (en) Xylitol-based anti-mucosal compositions and related methods and compositions
WO2010009091A3 (en) Anti-inflammatory and anti-allergy extracts from nettle
WO2013177468A3 (en) Methods and compositions for modulating apolipoprotein(a) expression
BRPI0822955A2 (pt) método para operar um elevdor em um modo de emergência, e, elevador.
WO2009049284A3 (en) Compositions and methods for improved glycoprotein sialylation
BRPI0819495A2 (pt) "fragmento de ácido nucleico isolado, construção recombinante, célula de planta e método para reduzir a expressão de uma sequência alvo"
BRPI0914431A2 (pt) composição, película vazada e seca produzida a partir de uma composição e método para a redução do amarelamento em uma pelicula
WO2008156873A3 (en) Apoa-1 peptide mimetics
DK2089524T3 (da) DNase ekspression i rekombinante værtsceller
DK2274430T3 (da) Nerveregenererende celler med ændringer i dna-methylering
WO2009099467A3 (en) Cyclosporin compositions
CL2013001940A1 (es) Composicion que comprende al menos una fibra soluble y al menos uno seleccionado entre un probiotico vivo, un probiotico inactivo, un medio de cultivo de un probiotico y una combinacion de dos o mas de las tres opciones anteriores; y su uso para aliviar, tratar y/o prevenir sintomas y/o condiciones relacionadas con estres cronico.
EP2031687A4 (en) REINTITANE OR TITANIUM ALLOY SEPARATOR FOR FESTPOLYMER FUEL CELL AND METHOD FOR THE PRODUCTION THEREOF
WO2007080546A3 (en) Compositions and methods useful for treatment of respiratory illness
WO2008138958A3 (de) Schaltungsanordnung und verfahren zum betreiben einer energiespeicheranordnung

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL